Jemal M - Search Results

1

Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects.

Liao WC, Vesterqvist O, Delaney C, Jemal M, Ferreira I, Ford N, Swanson B, Uderman H. Liao WC, et al. Among authors: jemal m. Br J Clin Pharmacol. 2003 Oct;56(4):395-406. doi: 10.1046/j.1365-2125.2003.01888.x. Br J Clin Pharmacol. 2003. PMID: 12968984 Free PMC article. Clinical Trial.

2

Disposition and safety of omapatrilat in subjects with renal impairment.

Sica DA, Liao W, Gehr TW, Khan S, Jemal M, Delaney CL, Ferreira IM, Malhotra BK. Sica DA, et al. Among authors: jemal m. Clin Pharmacol Ther. 2000 Sep;68(3):261-9. doi: 10.1067/mcp.2000.109033. Clin Pharmacol Ther. 2000. PMID: 11014407 Clinical Trial.

3

Omapatrilat in patients with hepatic cirrhosis. Pharmacodynamics and pharmacokinetics.

O'Grady P, Vesterqvist O, Malhotra B, Manning J, Jemal M, Ge G, Mangold B. O'Grady P, et al. Among authors: jemal m. Eur J Clin Pharmacol. 2001 Jun;57(3):249-57. doi: 10.1007/s002280100291. Eur J Clin Pharmacol. 2001. PMID: 11497341

4

Fosinopril: pharmacokinetics and pharmacodynamics in Chinese subjects.

Ding PY, Chu KM, Hu OY, Huang GM, Jeng JJ, Chang A, Delaney CL, MacAskill M, Yang BC, Jemal M, Smith R, Liao WC. Ding PY, et al. Among authors: jemal m. J Clin Pharmacol. 1999 Feb;39(2):155-60. doi: 10.1177/00912709922007705. J Clin Pharmacol. 1999. PMID: 11563407 Clinical Trial.

5

Pharmacodynamics and pharmacokinetics of omapatrilat in heart failure.

Kostis JB, Klapholz M, Delaney C, Vesterqvist O, Cohen M, Manning JA Jr, Jemal M, Kollia GD, Liao WC. Kostis JB, et al. Among authors: jemal m. J Clin Pharmacol. 2001 Dec;41(12):1280-90. doi: 10.1177/00912700122012869. J Clin Pharmacol. 2001. PMID: 11762555 Clinical Trial.

6

Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects.

Kasichayanula S, Boulton DW, Luo WL, Rodrigues AD, Yang Z, Goodenough A, Lee M, Jemal M, LaCreta F. Kasichayanula S, et al. Among authors: jemal m. Br J Clin Pharmacol. 2014 Nov;78(5):1122-34. doi: 10.1111/bcp.12425. Br J Clin Pharmacol. 2014. PMID: 24837659 Free PMC article. Clinical Trial.

7

LC/MS/MS determination of omapatrilat, a sulfhydryl-containing vasopeptidase inhibitor, and its sulfhydryl- and thioether-containing metabolites in human plasma.

Jemal M, Khan S, Teitz DS, McCafferty JA, Hawthorne DJ. Jemal M, et al. Anal Chem. 2001 Nov 15;73(22):5450-6. doi: 10.1021/ac010532d. Anal Chem. 2001. PMID: 11816572

8

Effect of the amount of internal standard on the precision of an analytical method.

Jemal M, Bergum J. Jemal M, et al. J Clin Pharmacol. 1992 Jul;32(7):676-7. doi: 10.1002/j.1552-4604.1992.tb05781.x. J Clin Pharmacol. 1992. PMID: 1640007

9

Metabolism of [14C]gemopatrilat after oral administration to rats, dogs, and humans.

Wait JC, Vaccharajani N, Mitroka J, Jemal M, Khan S, Bonacorsi SJ, Rinehart JK, Iyer RA. Wait JC, et al. Among authors: jemal m. Drug Metab Dispos. 2006 Jun;34(6):961-70. doi: 10.1124/dmd.105.007500. Epub 2006 Mar 15. Drug Metab Dispos. 2006. PMID: 16540589 Clinical Trial.

10

Disposition of radiolabeled ifetroban in rats, dogs, monkeys, and humans.

Dockens RC, Santone KS, Mitroka JG, Morrison RA, Jemal M, Greene DS, Barbhaiya RH. Dockens RC, et al. Among authors: jemal m. Drug Metab Dispos. 2000 Aug;28(8):973-80. Drug Metab Dispos. 2000. PMID: 10901709 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

157 results

Search Page

Filters